🔗 Share this article

A senior health officer was removed from oversight in an key medical study concerning hormone suppressants following claims regarding preconceived views surfaced.

Reported Intervention Resulted in Study Suspension

According to news reports, Prof Jacob George, the chief medical and scientific officer at the regulatory agency, raised worries that led to the pausing of the government-funded Pathways trial in February.

The regulator declared on Saturday that George would recuse him from any role with the trial after skeptical social media posts made previously were identified.

Content of Social Media Posts

Among a post, he described author J.K. Rowling being a “treasure in modern society.” In another, the professor stated that the refusal of basic biological fact is troubling” in relation to questions over an Olympic boxer’s sex.

The agency said how even though George’s comments were made prior to his appointment, he had been taken off from involvement with the study as an abundance of caution.

Particulars of the Halted Clinical Trial

This Pathways trial, that was designed to evaluate the impact from puberty blockers on young people exploring their gender, was scheduled to commence enrolling participants during the start of the year.

Yet, it was halted during February once its regulatory body voiced apprehensions about the welfare for young participants participating.

• The youngest subjects were expected to be ten to eleven for assigned female at birth while eleven to twelve for biological males.
• Its study leadership noted previously how the rigorous selection process meant those enrolled would probably be older.
• But, the regulator has now recommended the lowest age requirement should be fourteen owing to the “unquantified risk” for lasting biological harms.”

This study had planned to recruit around two hundred and twenty-six young people over the coming several years.

Background and the Cass Review

The study was initiated subsequent to a suggestion from a major report on children’s gender care, that determined how the robustness of studies claiming to prove the advantages of such treatment for children with gender dysphoria were “poor.”

Doctor Hilary Cass, who led that review, had earlier stated the report revealed a notably limited body of research” for the benefits of puberty blockers.

Dr. Cass noted, since there are medical professionals, children as well as parents who are convinced passionately of the positive outcomes, a study was the only way forward to make sense of this.”

Expert Criticism of the Action

Doctor Max Davie, an expert in adolescent medicine, stated there was no strong evidence-based justification to suspend the study.

“The tweets by Professor George offer a clear indication into his own opinions on this issue,” Dr. Davie stated. “He is free to hold any beliefs on gender identity he chooses, but what is unacceptable would be to permit these opinions to affect the execution of his regulatory responsibilities.”

He continued: “It must be understood, there exists no definitive research justification to stop this study. Although Prof George’s personal convictions is not the sole plausible cause for the MHRA’s abrupt reversal, they is the only one where we possess evidence.”

Regulator Response and Future Actions

An MHRA representative stated: “With all clinical trials, the MHRA’s primary concern remains the protection as well as wellbeing for the volunteers. As part of this duty, complicated studies are kept constantly being monitored and the MHRA keeps an ongoing conversation with study funders.”

“The MHRA has world-class medical, scientific and regulatory professionals who work as a cross-functional team to make research-informed judgments regarding clinical trials. These individuals will continue to work with the organizers to address the next steps productively.”

“After the finding regarding online activity made prior to his appointment, Professor Jacob George was recused from further oversight on this study as a preventative step.”